Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma versus serum effects on PF14-mRNA nanoparticle transfection
NL-OMON51048Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label trial of PepFect14 (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Cy5-mRNA uptake and EGFP expression. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
PepFect14
Beyond the preview
Go deeper on NL-OMON51048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51048.